Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes

Launched by UNIVERSITY OF PITTSBURGH · May 26, 2024

Keywords

ClinConnect Summary

This clinical trial is designed to better understand how the immune system reacts to kidney transplants and why some patients experience rejection while others do not. Specifically, researchers want to look closely at the different types of immune cells involved in kidney transplant rejection, how they interact, and the changes they undergo over time. By examining samples from kidney biopsies and blood, the study aims to identify patterns that could help predict who might face complications and who can expect a successful outcome after their transplant.

To participate, you need to be an adult who has received a kidney transplant from either a living or deceased donor. You also need to be able to understand and provide consent for the study. Throughout the trial, participants will provide various samples, including kidney biopsy tissues and blood, at specific times, such as during the transplant and follow-up visits. While the trial is not yet recruiting, it’s an important step toward improving care for kidney transplant recipients by gaining a deeper understanding of how rejection occurs and how it can be managed.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All adult living or deceased donor renal transplant recipients (age ≥ 18 years), irrespective of gender, race, or ethnic background.
• • 2. Able to understand and provide inform consent.
• Exclusion Criteria:
• • 1. Medical contraindications to undergo renal biopsy (use of long-term anticoagulation, low platelet count of \<100,000/uL)
• • 2. Cause of ESRD likely to recur in transplant: Hemolytic uremic syndrome (HUS)
• • 3. Not maintained on standard of care immunosuppression therapy (Thymoglobulin induction followed by tacrolimus and mycophenolate maintenance)